Cellectar compound to focus on children

The U.S. Food and Drug Administration has granted CLR 131, a compound developed by Madison-based Cellectar Biosciences, a special designation, the company announced.

The FDA grants a rare pediatric disease designation for such cancer-fighting compounds that might treat illnesses found primarily in children under the age of 18, including osteosarcoma, a form of bone cancer. Cellectar plans to begin clinical trials on CLR 131 later this year.